Pavlina Spiliopoulou[Author] - Search Results

Year	Number of Results
2014	1
2015	1
2016	3
2017	1
2018	1
2019	1
2020	1
2021	1
2022	3
2023	6
2024	3

1

Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).

Genta S, Lajkosz K, Yee NR, Spiliopoulou P, Heirali A, Hansen AR, Siu LL, Saibil S, Stayner LA, Yanekina M, Sauder MB, Keshavarzi S, Salawu A, Vornicova O, Butler MO, Bedard PL, Razak ARA, Rottapel R, Chruscinski A, Coburn B, Spreafico A. Genta S, et al. Among authors: spiliopoulou p. J Exp Clin Cancer Res. 2023 Oct 21;42(1):276. doi: 10.1186/s13046-023-02851-6. J Exp Clin Cancer Res. 2023. PMID: 37865776 Free PMC article.

2

All is not lost: learning from 9p21 loss in cancer.

Spiliopoulou P, Yang SYC, Bruce JP, Wang BX, Berman HK, Pugh TJ, Siu LL. Spiliopoulou P, et al. Trends Immunol. 2022 May;43(5):379-390. doi: 10.1016/j.it.2022.03.003. Epub 2022 Apr 1. Trends Immunol. 2022. PMID: 35379580 Free article. Review.

3

Promising and Minimally Invasive Biomarkers: Targeting Melanoma.

Spiliopoulou P, Holanda Lopes CD, Spreafico A. Spiliopoulou P, et al. Cells. 2023 Dec 20;13(1):19. doi: 10.3390/cells13010019. Cells. 2023. PMID: 38201222 Free PMC article. Review.

4

Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents.

Janse van Rensburg HJ, Spiliopoulou P, Siu LL. Janse van Rensburg HJ, et al. Among authors: spiliopoulou p. Oncologist. 2022 May 6;27(5):352-362. doi: 10.1093/oncolo/oyac047. Oncologist. 2022. PMID: 35285488 Free PMC article. Review.

5

Virotherapy: cancer gene therapy at last?

Bilsland AE, Spiliopoulou P, Evans TR. Bilsland AE, et al. Among authors: spiliopoulou p. F1000Res. 2016 Aug 30;5:F1000 Faculty Rev-2105. doi: 10.12688/f1000research.8211.1. eCollection 2016. F1000Res. 2016. PMID: 27635234 Free PMC article. Review.

6

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers.

Spiliopoulou P, Vornicova O, Genta S, Spreafico A. Spiliopoulou P, et al. Int J Mol Sci. 2023 Jan 9;24(2):1294. doi: 10.3390/ijms24021294. Int J Mol Sci. 2023. PMID: 36674809 Free PMC article. Review.

7

Targeting T regulatory (T_reg) cells in immunotherapy-resistant cancers.

Spiliopoulou P, Kaur P, Hammett T, Di Conza G, Lahn M. Spiliopoulou P, et al. Cancer Drug Resist. 2024 Jan 12;7:2. doi: 10.20517/cdr.2023.46. eCollection 2024. Cancer Drug Resist. 2024. PMID: 38318526 Free PMC article. Review.

8

Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma.

Lee CL, O'Kane GM, Mason WP, Zhang WJ, Spiliopoulou P, Hansen AR, Grant RC, Knox JJ, Stockley TL, Zadeh G, Chen EX. Lee CL, et al. Among authors: spiliopoulou p. Mol Cancer Ther. 2024 Mar 4;23(3):394-399. doi: 10.1158/1535-7163.MCT-23-0460. Mol Cancer Ther. 2024. PMID: 38015561 Free PMC article.

9

Metronomic oral cyclophosphamide in relapsed ovarian cancer.

Spiliopoulou P, Hinsley S, McNeish IA, Roxburgh P, Glasspool R. Spiliopoulou P, et al. Int J Gynecol Cancer. 2021 Jul;31(7):1037-1044. doi: 10.1136/ijgc-2021-002467. Epub 2021 May 20. Int J Gynecol Cancer. 2021. PMID: 34016703

10

Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.

Spiliopoulou P, Arkenau HT. Spiliopoulou P, et al. World J Gastroenterol. 2014 Aug 14;20(30):10288-95. doi: 10.3748/wjg.v20.i30.10288. World J Gastroenterol. 2014. PMID: 25132745 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

22 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year